Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade from ProteoGenix; catalogue PX-TA1033; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Cilgavimab is a monoclonal antibody targeting spike protein of SARS-CoV-2. This humanized biosimilar belong to the family of immunoglobulin G1- type. Cilgavimab has been recently approved by FDA and EMA to be used in emergency as prophylactic treatment against COVID-19 in association with Tixagevimab.
The spike protein is a transmembrane viral fusion protein. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism.
Cilgavimab biosimilar is a humanized antibody based on cross Mab technology. It is produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offer a product for research use only, not suitable for clinical or therapeutic use
Proteogenix launched a panel of antibodies against SARS-CoV-2 spike and the nucleocapsid. Each of them can recognize specifically SARS-CoV-2 antigens without cross reactivity with other human coronaviruses. Neutralizing antibodies are very promising in antiviral defense against the coronavirus disease 2019 (COVID-19) pandemic.
ProteoGenix catalogue number PX-TA1033.
Target: Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Molecular weight: 150kDa; Buffer: PBS pH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Cilgavimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
